SynAct Pharma AB: SynAct Pharma Year-end Report 2025

SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2025

"As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical execution, corporate development and external validation. Our focus remains firmly on advancing resomelagon (AP1189), our potential first-in-class non-suppressive therapy for inflammatory diseases, toward meaningful clinical and strategic value creation."

Jeppe Øvlesen
Chief Executive Officer and Board Member

Fourth quarter 2025 (October - December)

• The Group's net sales amounted to SEK 0 (0) thousand.
• Operating expenses amounted to SEK 22,720 (20,797) thousand, an increase of 9%.
• The Group's loss after tax amounted to SEK 22,929 (18,379) thousand.
• The Group's earnings per share before and after dilution amounted to -0.43 (-0.44) SEK.
• Cash flow from operating activities amounted to SEK -23,965 (-17,779) thousand.
• Cash flow from financing activities amounted to SEK -147 (40,199) thousand.
• Cash flow for the period amounted to SEK -24,112 (22,420) thousand.
• Cash and cash equivalents at the end of the period amounted to SEK 53,405 (61,209) thousand.

Twelve months 2025 (January - December)

• The Group's net sales amounted to SEK 0 (0) thousand.
• Operating expenses amounted to SEK 116,540 (89,980) thousand, an increase of 29%.
• The Group's loss after tax amounted to SEK 110,826 (82,401) thousand.
• The Group's earnings per share before and after dilution amounted to -2.17 (-2.08) SEK.
• Cash flow from operating activities amounted to SEK -97,330 (89,197) thousand.
• Cash flow from financing activities amounted to SEK 90,458 (87,405) thousand.
• Cash flow for the period amounted to SEK -6,872 (-1,792) thousand.

Significant events during the fourth quarter

• Oct 29 - Notice of Extraordinary General Meeting of SynAct Pharma AB on November 27, 2025.
• Nov 3 - 190 patients randomized in SynAct Pharma's Phase 2b study ADVANCE.
• Nov 27 - Report from the Extraordinary General Meeting of SynAct Pharma AB.
• Dec 11 - Nomination committee appointed ahead of AGM 2026 in SynAct Pharma AB.
• Dec 22 - SynAct Pharma management and Chairman of the Board have acquired shares.
• Dec 23 - SynAct Pharma Board of Directors and Management Enter Lock-up Agreements.

Significant events after the end of the period

• Jan 9 - The Board of Directors of SynAct Pharma AB (publ) has resolved on the repurchase of own shares.
• Jan 19 - SynAct Pharma appoints Malin Wikstrand as interim CFO.
• Jan 30 - SynAct Pharma initiates Phase 2 study in respiratory insufficiency.
• Feb 6 - SynAct Pharma announces that recruitment goal was reached in the Phase 2b ADVANCE study.
• Feb 17 - Repurchase of shares in Synact Pharma AB.

For further information about SynAct Pharma AB, please contact:
Jeppe Øvelsen
CEO, SynAct Pharma AB
Phone: [phone]
E-mail: [e-mail]

Malin Wikstrand
Interim CFO, SynAct Pharma AB
Phone: [phone]
E-mail: [e-mail]

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

This information is information that SynAct Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-18 07:30 CET.